Short answer
ADC Therapeutics SA (ADCT) filed an 8-K current report with the SEC on October 13, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 3.02 (Unregistered Sales of Equity Securities), Item EX-99.1 (Exhibit EX-99.1). $86.6M private placement, including 12.9M shares at $1.42 and 48.1M pre-funded warrants, creating substantial dilution risk.
ADC Therapeutics SA 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $86.6M private placement, including 12.9M shares at $1.42 and 48.1M pre-funded warrants, creating substantial dilution risk
- $70.0M debt prepayment reduces term loans to $50.0M and removes scheduled amortization and minimum liquidity covenant
- $65.0M minimum trailing U.S. ZYNLONTA sales covenant adds execution pressure beginning December 31, 2026
- Lender warrant exercise price cut from $8.30 to $1.00 on 527,295 shares, increasing potential dilution
- HCR royalty terms eased on change of control, but debt cap falls to $50.0M and 9.8M HCR warrants reset to $0.10 per share
Item 2.02 · Results of Operations and Financial Condition
- Preliminary ZYNLONTA net product revenue released for Q3 2026, providing an early read on commercial performance
- Preliminary cash and cash equivalents as of September 30, 2026, relevant to liquidity and funding runway
- Figures remain unaudited and subject to material revision before final quarterly results
Item 3.02 · Unregistered Sales of Equity Securities
- Private Placement, Lender Warrants and HCR Warrants represent unregistered equity-linked issuances
- Investors should assess dilution, warrant overhang and potential changes to ADC Therapeutics’ capital structure
- Terms and share counts are contained under Item 1.01, which governs the transaction details
Item EX-99.1 · Exhibit EX-99.1
- $86.6M PIPE: 12.9M shares at $1.42 and pre-funded warrants for 48.1M shares at $1.32, creating substantial dilution risk
- Expected net PIPE proceeds $76.3M, extending anticipated cash runway into 2029 and funding ZYNLONTA Phase 3 studies
- $70.0M loan prepayment reduces senior secured debt to $50.0M, with bullet maturity in August 2029 and no minimum liquidity covenant
- HCR removes $150M change-of-control payment, but lowers permitted third-party debt to $50.0M and retains royalty obligations
- Preliminary Q3 ZYNLONTA revenue approximately $21.0M and cash $189.2M as of September 30, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADC Therapeutics SA 8-K filings
Get the next ADCT 8-K as it lands
Follow ADCT for push alerts, or ask the research agent what this filing means.